Clinical Trials
36 trialsAMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
ECTOP-1004
Fudan University
A Single-arm Exploratory Study of Neoadjuvant Therapy
Guangzhou Institute of Respiratory Disease
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Fujian Cancer Hospital
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Hunan Cancer Hospital
The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.
National Taiwan University Hospital
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Peking University People's Hospital
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
Tianjin Medical University Cancer Institute and Hospital
TACTICAL
University College, London
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
Samsung Medical Center
TCM in the Treatment of Lung Adenocarcinoma
Henan University of Traditional Chinese Medicine
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Henan Cancer Hospital
Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene
Sun Yat-sen University
Geber
Fujian Cancer Hospital
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
Henan Cancer Hospital
Benefit
Peking University Cancer Hospital & Institute
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
First People's Hospital of Hangzhou
CTCs detection
Third Military Medical University
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Shanghai Chest Hospital
Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Anhui Provincial Hospital
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
First People's Hospital of Hangzhou
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2
People's Hospital of Guangxi Zhuang Autonomous Region
Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Hunan Province Tumor Hospital
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
cVATS
The First Affiliated Hospital of Guangzhou Medical University
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
National Cancer Center, Korea
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)